TPCN2 and malignant colon neoplasm: Carriage of TPCN2 rs35264875: TA was associated with an increased risk of colon cancer susceptibility (OR: 1.03, 95% CI: 1.01–1.05, P = 0.00138**, vs. A/A), whereas carriage of P2RX4 rs28360472:GA was associated with a decreased risk of colon cancer susceptibility (OR: 0.77, 95% CI: 0.61–0.97, P = 0.028* vs. A/A) (see Table 4 and Fig. 2b).